Clay Siegall co-founded Seattle Genetics in 1998. He currently plays the role of President, Chief Executive Officer and Chairmen of the Board. Seattle Genetics uses cutting edge technology to target multiple types of cancer and autoimmune conditions. Seattle Genetics is known for its technology which uses antibody-based therapies to fight cancer.
In 2011 Seattle Genetics was granted accelerated approval from the United States Federal Drug Administration for multiple therapies including ADCETRIS (brentuximab vedotin). In August 2015 Seattle Genetics announced FDA Approval for ADCETRIS, and in October 2015 announced enrollment in phase 3 clinical trials of ADCETRIS. Seattle Genetics along with Takeda would use Brentuxima Vedotin in phase 3 clinical trials to test the effects of the drug against previously untreated Advanced Hodgkin Lymphoma.
Clay Siegall earned a Ph.D in Genetics from George Washington University following his B.S. in Zoology he obtained from the University of Maryland. Dr. Siegall has led Seattle Genetics to be very successful with ventures such as the initial public offering in 2011. Seattle Genetics also has many licenses for its Antibody-drug Conjugate(ADC) technology which has generated more than $300 million dollars in funding to the company. The licenses are entered with companies such as Pfizer, GlaxoSmithKline, Genetech, and AbbVie.
Siegall has had a long career in the pharmaceutical research world, and held positions with companies such as Bristol-Myers Squibb Pharmaceutical Research Insinuate, the National Cancer Institute, and the national Institutes of Health. Dr. Siegall also serves on the Board of Directors for the private biotechnology company Alder BioPharmaceuticals.
Since its creation in 1998 Seattle Genetics has received more than $675 million dollars in public and private financing thanks to the guidance and capital raising activities of Dr. Clay Siegal.